A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of Tofacitinib (Cp-690,550) In Chinese Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Conventional Synthetic Dmard
Phase of Trial: Phase III
Latest Information Update: 13 Feb 2019
At a glance
- Drugs Tofacitinib (Primary)
- Indications Psoriatic arthritis
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 19 Sep 2018 Planned number of patients changed from 153 to 195.
- 19 Sep 2018 Planned End Date changed from 7 May 2020 to 26 Nov 2020.
- 19 Sep 2018 Planned primary completion date changed from 7 May 2020 to 26 Nov 2020.